Nuvalent (NUVL) Interest Coverage Ratio Growth (1y) (2021 - 2026)
Nuvalent (NUVL) Interest Coverage Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 787.12% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -100.36% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 73.00% |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 9.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.57% |
| Dec 31, 2025 | 0.93% |
| Sep 30, 2025 | -112.60% |
| Jun 30, 2025 | -91.66% |
| Mar 31, 2025 | 99.25% |
| Dec 31, 2024 | -109.63% |
| Sep 30, 2024 | 99.58% |
| Jun 30, 2024 | 99.32% |
| Mar 31, 2024 | 35.74% |
| Dec 31, 2023 | 99.53% |
| Sep 30, 2023 | -25.90% |
| Jun 30, 2023 | -34.04% |
| Mar 31, 2023 | -240.92% |
| Dec 31, 2022 | -2,833.23% |
| Dec 31, 2021 | -39.30% |